A coordinated day of protest across England has sharpened the dispute over Palantir’s role in the NHS, while a formal objection campaign has brought tens of thousands of patients’ data-protection requests into the debate. On 1 October, demonstrations outside hospitals and NHS offices culminated in a rally at the company’s London headquarters. Separately, 45,108 people lodged objections with NHS England over the use of their health information through the Federated Data Platform.
Actions across England converge on London
About 40 events took place around the country, directed at NHS trusts and integrated care organisations. The London gathering formed the final focal point of the day, bringing the national contract question to the company’s base in the capital. Protesters called for the health service to end its relationship with Palantir and for the contract not to continue into its next phase.
The actions reflect a dispute that combines questions about public procurement, health-data governance and the suitability of a private technology supplier for a sensitive national service. Demonstrators have cited Palantir’s work for US immigration enforcement and the Israeli military as reasons they oppose its involvement. Those concerns are part of the campaign against the contract; they do not, on their own, establish that NHS patient information has been used improperly.
What the objections ask NHS England to do
The 45,108 objections invoke data-protection rights and ask NHS England to protect the individuals’ health information from use through the platform. The requests were submitted as a collective legal statement coordinated by a campaign group. They are requests for action, not a ruling that the platform is unlawful, and the total does not mean that NHS England has accepted every objection or stopped processing the data concerned.
That distinction matters. A formal objection starts a process for the public body to consider the request under data-protection law. It is not the same as a finding by a regulator or court, nor does the headline number show how many requests will ultimately lead to a change in handling. The objections nevertheless give the contract review a concrete public dimension: thousands of people have actively asked for their records to be kept out of the system.
The platform is intended to connect information held across the health service so staff can coordinate work and make services more efficient. Its potential uses include helping organisations manage operational pressures, but the system’s stated purpose does not resolve public concerns about access, safeguards, trust or the choice of supplier.
A decision point in February 2027
The contract was awarded in 2023 to a consortium led by Palantir. It is valued at £330 million across a maximum seven-year period, while the initial three-year commitment ends on 15 February 2027. The agreement includes a break point at which the government can decide whether to continue. Ministers are reviewing the arrangement ahead of that date; no final decision to extend or end the deal has been announced.
A parliamentary committee has urged the government to use the February 2027 break clause and prepare an exit plan. That is a recommendation, rather than a settled government policy. The coming months therefore matter: the public contract is approaching a defined decision date, and the administration must weigh service continuity, the cost and practicality of changing suppliers, and public confidence in how sensitive information is handled.
Evidence and trust remain contested
Supporters of the platform have pointed to claimed improvements in operations, discharge delays and cancer-diagnosis timeliness. Those figures have themselves faced scrutiny, including concerns about whether the evidence behind some widely repeated benefits is sufficiently robust. The disagreement is not only about what the software can do, but also about how its effects are measured and explained.
The 1 October protests and the objections do not settle that argument. They do, however, make the decision harder to treat as a narrow technical procurement. For NHS England and ministers, the review now sits alongside a visible challenge over whether the public trusts the system, its safeguards and the company contracted to provide it. The February break clause offers a defined moment for that choice, but until a decision is made, the platform remains part of the NHS data infrastructure.
